{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:21:54Z","timestamp":1790709714313,"version":"4.1.0"},"reference-count":24,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Every year, dengue virus affects hundreds of millions of individuals worldwide. To date, there is no specific medication to treat dengue virus infections. Nucleobases, the base of a nucleoside without ribose, are understudied as potential treatments for viral infections. Antiviral nucleobases are converted in infected cells to their corresponding nucleoside triphosphate active form. Importantly, the conversion of nucleobases to their active nucleotide form and their antiviral effect can be enhanced when combined with de novo nucleotide biosynthesis inhibitors. In this work, we evaluated seven purine and pyrimidine nucleobases alone or combined with six purine or pyrimidine de novo nucleotide biosynthesis inhibitors, including novel prodrugs. Our study revealed that while a strong potentiation of purine nucleobases by purine de novo nucleotide biosynthesis inhibitors was observed, the pyrimidine nucleobases were not potentiated by pyrimidine de novo nucleotide biosynthesis inhibitors, possibly highlighting a significant difference between the modulation of purine versus pyrimidine de novo pathways and their impact on nucleobase potentiation. Most significant antiviral effects and potentiation were observed for Favipiravir, T-1105, and ribavirin nucleobases combined with purine nucleotide de novo synthesis inhibitors. These results are significant because drug combinations may solve the limited efficacy observed for some antiviral nucleobase drugs such as Favipiravir.<\/jats:p>","DOI":"10.3390\/molecules30020210","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:38:41Z","timestamp":1736221121000},"page":"210","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Purine but Not Pyrimidine De Novo Nucleotide Biosynthesis Inhibitors Strongly Enhance the Antiviral Effect of Corresponding Nucleobases Against Dengue Virus"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-8822","authenticated-orcid":false,"given":"Laurent F.","family":"Bonnac","sequence":"first","affiliation":[{"name":"Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6624-7001","authenticated-orcid":false,"given":"Christine D.","family":"Dreis","sequence":"additional","affiliation":[{"name":"Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Rai","sequence":"additional","affiliation":[{"name":"Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-6509","authenticated-orcid":false,"given":"Robert J.","family":"Geraghty","sequence":"additional","affiliation":[{"name":"Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother. AAC"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of Action of T-705 against Influenza Virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother. AAC"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.113.087247","article-title":"Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir)","volume":"84","author":"Naesens","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1592\/phco.21.1.11.34439","article-title":"Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians","volume":"21","author":"Stein","year":"2001","journal-title":"Pharmacotherapy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0163-7258(00)00048-6","article-title":"Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases","volume":"87","author":"Johansson","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2003.07.001","article-title":"Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases","volume":"100","author":"Johansson","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Qiu, L., Patterson, S.E., Bonnac, L.F., Geraghty, R.J., and Abd-Alla, A.M.M. (2018). Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis. PLoS Neglected Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006421"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Soto-Acosta, R., Edwards, T.C., Dreis, C.D., Krishna, V.D., Cheeran, M.C.J., Qiu, L., Xie, J., Bonnac, L.F., and Geraghty, R.J. (2021). Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies. Viruses, 13.","DOI":"10.3390\/v13122508"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Thaker, S.K., Ch\u2019ng, J., and Christofk, H.R. (2019). Viral hijacking of cellular metabolism. BMC Biol., 17.","DOI":"10.1186\/s12915-019-0678-9"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2304139120","DOI":"10.1073\/pnas.2304139120","article-title":"2-thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses","volume":"120","author":"Uemura","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virol.2021.09.009","article-title":"Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses","volume":"564","author":"Wang","year":"2021","journal-title":"Virology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e170236","DOI":"10.1172\/JCI170236","article-title":"Preparing for the next viral threat with broad-spectrum antivirals","volume":"133","author":"Karim","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Geraghty, R.J., Geraghty, R., Aliota, M., and Bonnac, L. (2021). Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses, 13.","DOI":"10.3390\/v13040667"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e01897","DOI":"10.1128\/AAC.01897-20","article-title":"A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19","volume":"64","author":"Doi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1093\/infdis\/jiad409","article-title":"Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza","volume":"230","author":"Hayden","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nguyen, T.H.T., Guedj, J., Anglaret, X., Laou\u00e9nan, C., Madelain, V., Taburet, A.-M., Baize, S., Sissoko, D., Pastorino, B., and Rodallec, A. (2017). Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Neglected Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005389"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sissoko, D., Laouenan, C., Folkesson, E., M\u2019Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., and Danel, C. (2016). Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002066"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e0086221","DOI":"10.1128\/JVI.00862-21","article-title":"SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway","volume":"95","author":"Chen","year":"2021","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Soto-Acosta, R., Jung, E., Qiu, L., Wilson, D.J., Geraghty, R.J., and Chen, L. (2021). 4,7-Disubstituted 7H-Pyrrolo[2,3-d]pyrimidines and Their Analogs as Antiviral Agents against Zika Virus. Molecules, 26.","DOI":"10.3390\/molecules26133779"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat. Protoc."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/2\/210\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:24:03Z","timestamp":1759919043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/2\/210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["molecules30020210"],"URL":"https:\/\/doi.org\/10.3390\/molecules30020210","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]}}}